Literature DB >> 11287808

Prognostic implications for gadolinium enhancement of the meninges in low-grade astrocytomas of childhood.

M D Hurwitz1, P C Burger, P T Goldthwaite, T Tihan, M D Wharam, P G Fisher.   

Abstract

BACKGROUND: Persistent gadolinium enhancement on MRI of the meninges in some children with low-grade astrocytomas (LGA) is a widely recognized phenomenon. The relationship of this finding with the clinical course is unclear.
METHODS: From a consecutive cohort of 282 children with pathologically confirmed LGA we identified all patients with asymptomatic gadolinium enhancement of the meninges found on surveillance MRI. A nested case-control study was performed, comparing patients with meningeal enhancement to controls without enhancement.
RESULTS: Twenty-one children were identified with meningeal enhancement. The median follow-up was 5.2 years with enhancement noted for a median of 2.2 years. The 5-year overall survival for this cohort was 91.2% (Greenwood SE 8.0%), and the 5-year progression-free survival was 20.9% (SE 11.9%). Five patients are now free of disease, while 15 continue to have stable disease. The overall and progression-free survival was not significantly different compared to controls.
CONCLUSIONS: Gadolinium enhancement of the meninges on MRI may occur in a significant number of children with LGA, particularly juvenile pilocytic astrocytoma, but does not appear to affect progression-free or overall survival. Change in management based on this finding alone is unwarranted. Copyright 2001 S. Karger AG, Basel

Entities:  

Mesh:

Year:  2001        PMID: 11287808     DOI: 10.1159/000056000

Source DB:  PubMed          Journal:  Pediatr Neurosurg        ISSN: 1016-2291            Impact factor:   1.162


  1 in total

1.  The value of tandem CSF/MRI evaluation for predicting disseminated disease in childhood central nervous system neoplasms.

Authors:  Judy Pang; Anuradha Banerjee; Tarik Tihan
Journal:  J Neurooncol       Date:  2007-11-07       Impact factor: 4.130

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.